Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Controlled, Phase 2b/3 Study to Assess the Efficacy and Safety of ABP-671 in Participants With Gout

NCT05818085 is registered in ClinicalTrials.gov with Atom Therapeutics Co., Ltd as lead sponsor.

NCT NCT05818085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05818085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Controlled, Phase 2b/3 Study to Assess the Efficacy and Safety of ABP-671 in Participants With Gout
Lead sponsor
Atom Therapeutics Co., Ltd
Phase
Phase 2/3
Overall status
Completed
Start date
August 11, 2023
Completion date
March 30, 2025
Enrollment
300 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

gout